All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study

References

• WallentinLKristensenSDAndersonJLHow can we optimize the processes of care for acute coronary syndromes to improve outcomes?Am Heart J2014168562263125440789
   PubMed Web of Science ®Google Scholar
• WhiteHDChewDPAcute myocardial infarctionLancet2008372963857058418707987
   PubMed Web of Science ®Google Scholar
• SmolinaKWrightFLRaynerMGoldacreMJDeterminants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database studyBMJ2012344d8059d805922279113
   PubMed Web of Science ®Google Scholar
• PedersenFButrymovichVKelbækHShort- and long-term cause of death in patients treated with primary PCI for STEMIJ Am Coll Cardiol201464202101210825457398
   PubMed Web of Science ®Google Scholar
• StegPGJamesSKAtarDBadanoLPLundqvistCBAuthors/Task Force MembersESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology ESCEur Heart J201233202569261922922416
   PubMed Web of Science ®Google Scholar
• HammCWBassandJPAgewallSESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology ESCEur Heart J201132232999305421873419
   PubMed Web of Science ®Google Scholar
• AmsterdamEAWengerNKBrindisRG2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation2014130252354239425249586
   PubMed Web of Science ®Google Scholar
• BriegerDAntithrombotic strategies to reduce adverse clinical outcomes in patients with acute coronary syndromeAm J Cardiol201211081200120622840845
   PubMed Web of Science ®Google Scholar
• ClarkMGBeaversCOsborneJManaging the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapyHeart Lung201544214114925592204
   PubMed Web of Science ®Google Scholar
• PiepoliMFCorràUDendalePChallenges in secondary prevention after acute myocardial infarction: A call for actionEur J Prev Cardiol201623181994200627600690
   PubMed Web of Science ®Google Scholar
• JernbergTHasvoldPHenrikssonMHjelmHThuressonMJanzonMCardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspectiveEur Heart J201536191163117025586123
   PubMed Web of Science ®Google Scholar
• ShoreSSmolderenKGKennedyKFHealth status outcomes in patients with acute myocardial infarction after rehospitalizationCirc Cardiovasc Qual Outcomes20169677778427780850
   PubMed Web of Science ®Google Scholar
• HannaEBChenAYRoeMTWiviottSDFoxCSSaucedoJFCharacteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary interventionJACC Cardiovasc Interv2011491002100821939940
   PubMed Web of Science ®Google Scholar
• RoeMTWhiteJAKaulPRegional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS TrialCirc Cardiovasc Qual Outcomes20125220521322373905
   PubMed Web of Science ®Google Scholar
• ChenHYTisminetzkyMLapaneKLDecade-long trends in 30-day rehospitalization rates after acute myocardial infarctionJ Am Heart Assoc2015411e00229126534862
   PubMed Web of Science ®Google Scholar
• RanasingheIWangYDharmarajanKHsiehAFBernheimSMKrumholzHMReadmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia among young and middle-aged adults: a retrospective observational cohort studyPLoS Med2014119e100173725268126
   PubMed Web of Science ®Google Scholar
• DunlaySMWestonSAKillianJMBellMRJaffeASRogerVLThirty-day rehospitalizations after acute myocardial infarction: a cohort studyAnn Intern Med201215711122751756
   PubMed Web of Science ®Google Scholar
• DharmarajanKHsiehAFLinZDiagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumoniaJAMA2013309435523340637
   PubMed Web of Science ®Google Scholar
• ArnoldSVSmolderenKGKennedyKFRisk factors for rehospitalization for acute coronary syndromes and unplanned revascularization following acute myocardial infarctionJ Am Heart Assoc201542e001352e00135225666368
   PubMed Web of Science ®Google Scholar
• OnderGMarengoniARussoPAdvanced age and medication prescription: more years, less medications? A nationwide report from the Italian medicines agencyJ Am Med Dir Assoc201617216817226441359
   PubMed Web of Science ®Google Scholar
• Degli EspostiLSangiorgiDBudaSDegli EspostiEScaglioneFTherapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ‘real-world’ retrospective cohort studyBMJ Open2016611e012003
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (AIFA, Agenzia Italiana del Farmaco)Guideline for the classification and conduction of the observational studies on medicines2010 Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdfhttps://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdfAccessed August 6, 2018
   Google Scholar
• Cardiovascular disease in Europe 2016: an epidemiological updateEur Heart J201637423182318327856561
   PubMedGoogle Scholar
• RoffiMPatronoCColletJP2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESCEur Heart J201637326731526320110
   PubMed Web of Science ®Google Scholar
• BarillàFPellicciaFBorziMOptimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of CardiologyJ Cardiovasc Med201718119
   Google Scholar
• BhattDLHulotJSMoliternoDJHarringtonRAAntiplatelet and anticoagulation therapy for acute coronary syndromesCirc Res2014114121929194324902976
   PubMed Web of Science ®Google Scholar
• BonacaMPBhattDLBraunwaldEDesign and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trialAm Heart J2014167443744424655690
   PubMed Web of Science ®Google Scholar
• WallentinLCommentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trialsEur Heart J2016374ehv499
   Web of Science ®Google Scholar
• BittlJABaberUBradleySMWijeysunderaDNDuration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery diseaseJ Am Coll Cardiol201668101116113927036919
   PubMed Web of Science ®Google Scholar
• CohenMLong-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarctionJ Thromb Thrombolysis201641346447426001907
   PubMed Web of Science ®Google Scholar
• MauriLKereiakesDJYehRWTwelve or 30 months of dual antiplatelet therapy after drug-eluting stentsN Engl J Med2014371232155216625399658
   PubMed Web of Science ®Google Scholar
• LeeCWAhnJMParkDWOptimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trialCirculation2014129330431224097439
   PubMed Web of Science ®Google Scholar
• HelftGStegPGLe FeuvreCStopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL random-ized trialEur Heart J20157ehv481
   Google Scholar
• ColletJPSilvainJBarthélémyODual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trialLancet201438499541577158525037988
   PubMed Web of Science ®Google Scholar
• AxonRNWilliamsMVHospital readmission as an accountability measureJAMA2011305550421285430
   PubMed Web of Science ®Google Scholar
• McIlvennanCKEapenZJAllenLAHospital readmissions reduction programCirculation2015131201796180325986448
   PubMed Web of Science ®Google Scholar
• KernDMMellströmCHuntPRLong-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured populationCurr Med Res Opin201632470371126709864
   PubMed Web of Science ®Google Scholar
• RoggeriAGnaviRDalmassoMResource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysisCrit Pathw Cardiol201312420420924240551
   PubMedGoogle Scholar